Leber B, Ruiz MT, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh AC. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer. 2025 Apr 15;131(8):e35845. doi: 10.1002/cncr.35845
Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Feb;21(5):579-91. doi: 10.1080/14796694.2025.2454895
Passamonti F, Parikh RC, Korgaonkar S, Chevli M, Yucel A, Rombi J, Zissler D, Davis KL, Slaff S. Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with myelofibrosis treated with fedratinib. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Leber B, Ruiz M, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Schuh AC. Real-World treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia in Canada. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Obeid E, Parikh RC, Esterberg E, Arondekar B, Hitchens A, Arruda LS, Niyazov A, Whitaker K. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States. Front Oncol. 2024 May 16;14:1341665. doi: 10.3389/fonc.2024.1341665
Razavi P, Ahmed M, Roush A, Parikh R, Hitchens A, Shen S, Safonov A, Jhaveri K, Robson M, Peacock N, Ma Y, Santarsiero E, Ganapathy V, Shah R, Amaefule A, Lteif A, Blakely J. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024 May;42(Suppl 16):e12533.
Ayodele O, Parikh RC, Esterberg E, Ajmera M, Goodwin B, Williams J, Desai NK, Katzka DA. Treatment patterns and persistent disease activity in patients with eosinophilic esophagitis: a retrospective cohort study. Gastro Hep Adv. 2024 Mar 2;3(5):659-70. doi: 10.1016/j.gastha.2024.02.007
Diez-Campelo M, Yucel A, Goyal RK, Parikh RC, Esterberg E, Jimenez M, Sluga-O'Callaghan M, Miteva D, Xiao H, Germing U. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228
Pluard T, Sandin R, Parikh R, Ward M, Stansfield L, Nham T, Esterberg L, Cha-Silva A, Shah B. Health care resource utilization and cost comparison among palbociclib, abemaciclib, and ribociclib in US patients with HR+/HER2− metastatic breast cancer. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S17-8. doi: 10.18553/jmcp.2023.29.10-a.s1
Jimenez M, Zanotti G, Parikh RC, Esterberg E, Suarez LA. A retrospective medical record review of first-line sunitinib administration schedules and outcomes among patients with metastatic renal cell carcinoma in Latin America. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S45. doi: 10.1016/j.jval.2023.03.2298
Fasching PA, Hall PS, Chang L, Parikh R, Hitchens A, Davis KL, Sjekloca N, Summerhayes M, Ntalla I, Derrien Ansquer V, Bergamaco E, Ghabaireh M. Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER). Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 11, 2023. Berlin, Germany.
Oikonomidou O, Galve-Calvo E, Wockel A, Parikh R, Hitchens A, Chen C, Gauthier E, Li B, Derrien Ansquer V, Frugier G, Jimenez M, Davis KL, Broughton EI. Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2_ advanced breast cancer in Europe. Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 2023. Berlin, Germany.
Kaul S, Gosmanova EO, Castriota F, Hitchens A, Candrilli S, Parikh R, Esterberg E, Ayodele O. Recent trends in hypoparathyroidism-related inpatient and emergency department admissions and costs in the United States. J Endocr Soc. 2023 Apr 18;7(5):bvad050. doi: 10.1210/jendso/bvad050.
Bhandari NR, Hess LM, Parikh RC, Sireci AN, Krein PM, Kaye JA. Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the United States. Per Med. 2023 Mar;20(2):131-42. doi: 10.2217/pme-2022-0050
Parikh RC, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Respiratory syncytial virus–attributable hospitalizations among adults ≥60 years in the United States – a comparison by race/ethnicity. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Parikh RC, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Respiratory syncytial virus versus influenza hospitalizations among adults ≥60 years in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Diez-Campelo M, Yucel A, Goyal R, Parikh R, Dhuliawala S, Jimenez M, Sluga-O'Callaghan M, Hughes C, Tang D, Germing U. Systemic therapy utilization and hematologic outcomes in lower-risk myelodysplastic syndromes (LR-MDS): findings from a real-world medical record review study in the US, UK, and Europe (EU). Poster presented at the 2022 European Hematology Association Hybrid Congress; June 10, 2022. Vienna, Austria.
Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Parikh R, Hess LM, Esterberg E, Bhandari NR, Kaye JA. Diagnostic characteristics, treatment patterns, and clinical outcomes for US patients with advanced/metastatic medullary thyroid cancer: a retrospective medical record review. J Thyroid Res. 2022;15(2). doi: 10.1186/s13044-021-00119-9
Germing U, Goyal RK, Yucel A, Parikh RC, Jimenez M, Sluga-O'Callaghan M, Tang D, Hughes C, Diez-Campelo M. Real-world evidence on treatment utilization in lower-risk myelodysplastic syndromes: findings from a medical record review in the United States. Poster presented at the 63rd ASH Annual Meeting and Exposition; December 11, 2021. Atlanta, GA. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):4666. doi: 10.1182/blood-2021-145576
Inui K, Sato M, Esterberg E, Parikh RC, Kimura S, Torisu-Itakura H. Treatment practices and costs among patients with psoriatic arthritis: a Japanese hospital claims database analysis. Mod Rheumatol. 2021 Nov;31(6):1179-91. doi: 10.1080/14397595.2021.1886629
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871
Obeid E, Parikh R, Esterberg E, Arondekar B, Hitchens A, Shahied Arruda L, Niyazov A. Genetic Counseling (GC) patterns by practice setting among patients (pts) with germline BRCA1/2 mutated (gBRCA1/2mut) Advanced Breast Cancer (ABC): results from a US retrospective medical records review study. Poster presented at the 2020 Virtual NSGC 39th Annual Conference; November 18, 2020.
Ayodele O, Parikh RC, Ajmera A, Esterberg E, Desai NK, Williams J, Katzka DA. Assessing the diagnostic journey, burden of disease, and treatment patterns in patients with eosinophilic esophagitis in a real world setting. Poster presented at the ACG 2020 Virtual Annual Scientific Meeting; October 23, 2020.
Ayodele O, Parikh RC, Esterberg E, Ajmera M, Goodwin B, Desai NK, Williams J, Katzka DA. Characterizing the burden of disease in younger children, adults, and older adults with eosinophilic esophagitis in a real world setting. Poster presented at the ACG 2020 Virtual Annual Scientific Meeting; October 23, 2020.
Tomita T, Sato M, Esterberg E, Parikh RC, Hagimori K, Nakajo K. Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: a hospital claims database analysis. Mod Rheumatol. 2020 Jun 19;1-11. doi: 10.1080/14397595.2020.1775927
Parikh RC, Niyazov A, Esterberg E, Arondekar B, Hitchens A, Shahied Arruda L, Obeid E. Real-world patient demographics, treatment patterns and healthcare resource utilization (HRU) among Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced Breast Cancer (ABC) patients with BRCA1/2 Mutations (BRCA1/2MUT). Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S79. doi: 10.1016/j.jval.2020.04.094
Parikh R, Niyazov A, Esterberg E, Arondekar B, Arruda L, Obeid E. Real-World treatment patterns and safety outcomes among patients with HER2 negative advanced breast cancer and BRCA1/2 mutations: evidence from a retrospective medical record review study in the United States. Poster presented at the 2020 AMCP (Conference cancelled); April 21, 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr; 26(4-a):S16.
Parikh RC, Niyazov A, Esterberg E, Arondekar B, Hitchens A, Shahied Arruda L, Obeid E. Patient (Pt) demographics, clinical characteristics and treatment patterns among pts with Germline Breast Cancer Susceptibility Gene 1/2 mutated (gBRCA1/2mut) HER2– Advanced Breast Cancer (ABC): results from a US real-world study. Poster presented at the 2020 Miami Breast Cancer Conference; March 5, 2020. Miami Beach, FL.
Tomita T, Sato M, Parikh RC, Esterberg E, Kurosky SK, Hagimori K, Nakajo K. Treatment patterns among Japanese patients with ankylosing spondylitis (AS): hospital claims database analysis. Poster presented at the 29th Japanese Spondyloarthritis Society Conference; September 2019.
Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019 Aug;10(4):674-87. doi: 10.21037/jgo.2019.03.11
Ajmera M, Parikh R, Meyers J. Autoimmune disorders among adults with asthma: an economic outlook. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.
Parikh RC, Nagar SP, Ajmera M, Kurosky SK. Nationwide trends in prescription opioid use among adults- a pre-public health emergency perspective on the opioid crisis. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.
Klein A, Parikh R, Kurosky S, Esterberg E, Kaye JA. Clinical characteristics, treatment patterns, and healthcare resource utilization in patients with advanced urothelial carcinoma after progression on platinum-based therapy: a medical record review study in the United States and Canada. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.
Klein A, Parikh R, Kurosky S, Esterberg E, Kaye JA. Real-world clinical characteristics, treatment patterns, and healthcare resource utilization among patients with advanced urothelial carcinoma in North America and Europe. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.
Parikh R, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Mann H, Wang H. Treatments and health care utilisation (HCU) in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) following initial platinum therapy in the United Kingdom. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.
Parikh RC, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Sawyer W, Wang H. Treatments and health care utilisation (HCU) following initial platinum therapy in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): a medical record review in Germany. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.
Parikh RC, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Sawyer W, Wang H. Assessment of treatments and health care utilisation (HCU) in Spain following initial platinum therapy for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.
Saif W, Parikh R, Ray D, Kaye JA, Kurosky S, Thomas S, Halfdanarson T, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the NANETS Regional NET Education Conference; September 15, 2018. New Brunswick, NJ. Previously presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Saif WM, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018 Jun 1; 36(15_suppl):e16174. doi: 10.1200/JCO.2018.36.15_suppl.e16174
Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. Clin Sarcoma Res. 2018 May 3;8:8. doi: 10.1186/s13569-018-0094-x
Trantham L, Klein AB, Parikh RC, Kurosky S, Zhang Y, Levine CA, Kaye JA. Unresectable, locally advanced, stage III non-small cell lung cancer: real-world clinical characteristics, treatment patterns, and health care resource utilization in Europe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.289
Kurosky S, Klein AB, Parikh RC, Trantham L, Zhang Y, Levine CA, Kaye JA. Clinical characteristics, treatment patterns, and health care resource utilization in unresectable, locally advanced, stage III non-small cell lung cancer: a medical record review study in the United States and Canada. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.286
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review. Int J Gynecol Cancer. 2018 May;20(4):738-48. doi: 10.1097/IGC.0000000000001222
Nagar SP, Parikh RC, Davis KL. Prescription opioid use among children and adolescents with asthma in the United States: national estimates from 2011 to 2015. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S237. doi: 10.1016/j.jval.2018.04.1602
Parikh RC, Klein AB, Kurosky S, Trantham L, Zhang Y, Levine CA, Kaye JA. Programmed cell death LIGAND-1 testing among patients with metastatic non-small cell lung cancer: a multinational medical record review study. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S50. doi: 10.1016/j.jval.2018.04.1821